James R. Anderson

James Robert Anderson KC (12 June 1864 – 7 April 1913) was a lawyer in the Colony and State of South Australia. He was unique in South Australia and possibly Australia in serving as Attorney General without being a Member of Parliament. Provided by Wikipedia
Showing 1 - 5 results of 5 for search 'James R. Anderson', query time: 0.02s Refine Results
  1. 1
    La mort naturelle d'une femelle chimpanzé âgée au sein de son groupe

    La mort naturelle d'une femelle chimpanzé âgée au sein de son groupe by James R Anderson

    Published 2015-03-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Introduction au dossier spécial : Collaborations franco-japonaises en primatologie

    Introduction au dossier spécial : Collaborations franco-japonaises en primatologie by James R Anderson, Tetsuro Mastuzawa

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    La non-réciprocité d’un tiers induit la méfiance chez les singes capucins

    La non-réciprocité d’un tiers induit la méfiance chez les singes capucins by James R Anderson, Benoit Bucher, Margaux Levasseur, Kazuo Fujita

    Published 2016-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.

    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. by Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study

    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study by Graham Cohen, Bernardo Rapoport, Sze W. Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P. Brown, Robert M. Zielinski, Eva Muñoz Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: